News and Media

Latest News Release

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...


Company News

Cardinal Health Announces New Strategic Distribution Agreements at TCT 2016 to Expand Cordis’ Cardiovascular Product Offerings

DUBLIN, Ohio, Oct. 28, 2016 — Cardinal Health today announced several new strategic distribution agreements that will enable Cordis, Cardinal Health’s interventional vascular business, to rapidly expand its product portfolio in select countries globally. These distribution agreements, which add coronary stents and percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, expand Cordis’ portfolio of innovative products that support the treatment of patients undergoing percutaneous coronary intervention (PCI) from access to intervention and closure.

Cordis and Cardinal Health will showcase their competitive and value-based product and services offering, significantly expanded through these new innovative distribution collaborations, at the 28th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, held October 29 – November 2 in Washington, D.C. (booth #1306).

“In the past year, since becoming a Cardinal Health company, we have executed several key strategic collaborations that strengthen the Cordis product and solutions offering in interventional cardiology,” said David Wilson, president of Cordis. “We strongly believe that agreements like these provide the opportunity to rapidly expand our portfolio and deliver increased value to customers around the world. We will continue to explore additional opportunities to broaden the global Cordis offering.”

New and Expanded Strategic Distribution Agreements

  • Cardinal Health has expanded its current distribution agreement with Biosensors that will enable Cordis to be the exclusive distributor for Biosensors’ coronary interventional products in Japan. Cordis will now distribute Biosensors’ coronary stent portfolio in approximately 27 countries in Europe, the Middle East, and Africa (EMEA), in addition to Japan, Australia and New Zealand. Biosensors (TCT booth #1808), will also present two-year data on LEADERS FREE, the landmark trial evaluating the BioFreedom™ polymer-free drug-coated stent in high bleeding risk patients with one month dual antiplatelet therapy, during the late breaking session on Sunday, October 30 in the Main Arena at 12:45 p.m.
  • Cardinal Health signed a distribution agreement with Kaneka that enables Cordis to distribute Kaneka’s PTCA balloon catheters in EMEA, and select countries in Asia Pacific and Latin America (LATAM). In Japan, Korea, Australia, and New Zealand, Cordis will sell versions of Kaneka’s PTCA balloon catheters under the names of NEON™ and NEON™ NC. In China, Cordis will be the sole distributor of Ikazuchi Rev and Fortis II, under Kaneka’s brand. Upon Kaneka receiving CE-mark and other regulatory clearances in EMEA, China and select LATAM countries, Cordis will begin to sell the Ikazuchi Zero and Raiden 3 PTCA balloons under the Kaneka brand name.
  • Cardinal Health signed a distribution agreement with Meril (TCT booth #1513) that enables Cordis to sell Meril’s MOZEC™ and MOZEC™ NC Rx PTCA balloon dilatation catheters in the United States and Canada.
  • Cardinal Health signed a strategic agreement with Tryton and is committed to a long-term relationship in the United States where Tryton is currently seeking regulatory approval for their Coronary Side Branch Stent. For more information about Tryton’s Side Branch Stent, please visit the company’s TCT booth #1343 or attend Tryton’s breakfast symposium, “Establishing the New Standard: Definitive Treatment for Complex Bifurcation Lesions,” on Monday, October 31 at 6:30 a.m.

“With Cordis’ proud legacy of delivering innovative solutions in the cardiovascular care space and the business and operational expertise of Cardinal Health, we have established an unmatched, combined offering. Our vision is to make significant contributions to the healthcare system by bringing value-based products and solutions that our customers and their patients are seeking,” said Wilson.


About Cardinal Health 
Cardinal Health, Inc., a global health services and products company, brings scaled solutions that help our customers thrive in a changing world. We improve the cost effectiveness of healthcare through solutions that improve the efficiency of the supply chain; optimize the process and performance of healthcare; provide clinically-proven, daily-use medical products and pharmaceuticals; and connect patients, providers, payers, pharmacists, and manufacturers for seamless care coordination and better patient management. Backed by nearly 100 years of experience, we rank among the top 50 on the Fortune 500 and among the Fortune Global 100. We support our partners with more than 37,000 employees in nearly 60 countries worldwide. For more information, visit and @CardinalHealth on Twitter.

More Company News

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...


By Victor Crawford, Chief Executive Officer of the Pharmaceutical segment at Cardinal Health


Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve...


Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will...

View all company news »

* Required Fields